PE20080661A1 - COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa - Google Patents

COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa

Info

Publication number
PE20080661A1
PE20080661A1 PE2007001213A PE2007001213A PE20080661A1 PE 20080661 A1 PE20080661 A1 PE 20080661A1 PE 2007001213 A PE2007001213 A PE 2007001213A PE 2007001213 A PE2007001213 A PE 2007001213A PE 20080661 A1 PE20080661 A1 PE 20080661A1
Authority
PE
Peru
Prior art keywords
composition
inhibitor
factor
pharmaceutical composition
weight
Prior art date
Application number
PE2007001213A
Other languages
English (en)
Spanish (es)
Inventor
Omar Abdelfattah Abu-Baker
Jong Hu
Kimberly Anne Lamey
Robert Francis Leposki
Rennan Pan
Kamlesh Rameshchandra Patel
Rahul Parashar Shukla
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38835794&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20080661(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of PE20080661A1 publication Critical patent/PE20080661A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2007001213A 2006-09-12 2007-09-10 COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa PE20080661A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82531406P 2006-09-12 2006-09-12

Publications (1)

Publication Number Publication Date
PE20080661A1 true PE20080661A1 (es) 2008-06-12

Family

ID=38835794

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001213A PE20080661A1 (es) 2006-09-12 2007-09-10 COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa

Country Status (16)

Country Link
US (1) US20090285887A1 (https=)
EP (1) EP2061439A1 (https=)
JP (1) JP2010502762A (https=)
KR (1) KR20090052346A (https=)
CN (1) CN101516355A (https=)
AR (1) AR062721A1 (https=)
AU (1) AU2007296311A1 (https=)
BR (1) BRPI0716234A2 (https=)
CA (1) CA2662542A1 (https=)
CL (1) CL2007002618A1 (https=)
EA (1) EA200970267A1 (https=)
IL (1) IL197295A0 (https=)
MX (1) MX2009002669A (https=)
PE (1) PE20080661A1 (https=)
TW (1) TW200824723A (https=)
WO (1) WO2008031782A1 (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2502911T (lt) 2004-06-24 2017-09-11 Vertex Pharmaceuticals Incorporated Atp surišančios kasetės transporterių moduliatoriai
WO2007079139A2 (en) 2005-12-28 2007-07-12 Vertex Pharmaceuticals, Inc. Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
US12458635B2 (en) 2008-08-13 2025-11-04 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administrations thereof
US20100074949A1 (en) 2008-08-13 2010-03-25 William Rowe Pharmaceutical composition and administration thereof
SI2408750T1 (sl) 2009-03-20 2015-11-30 Vertex Pharmaceuticals Incorporated Postopek za izdelavo modulatorjev cistično-fibroznega transmembranskega regulatorja prevodnosti
SMT202000093T1 (it) * 2009-06-16 2020-03-13 Pfizer Forme di dosaggio di apixaban
WO2010151745A1 (en) * 2009-06-25 2010-12-29 Elite Laboratories, Inc. Oral dosage forms
SI2538925T1 (sl) 2010-02-25 2016-04-29 Bristol-Myers Squibb Company Apiksaban formulacije
AU2015271995A1 (en) * 2010-02-25 2016-01-21 Bristol-Myers Squibb Holdings Ireland Apixaban formulations
RU2013113627A (ru) * 2010-08-27 2014-10-10 Вертекс Фармасьютикалз Инкорпорейтед Фармацевтическая композиция и ее введения
AU2011315819B2 (en) 2010-10-15 2014-12-11 Brain Sentinel, Inc. Method and apparatus for detecting seizures
EP2554159A1 (en) * 2011-08-04 2013-02-06 ratiopharm GmbH Dosage forms comprising apixaban and content uniformity enhancer
EP2819670A1 (en) 2012-02-27 2015-01-07 Vertex Pharmaceuticals Incorporated Pharmaceutical composition and administration thereof
KR101378973B1 (ko) * 2012-04-13 2014-03-28 한미약품 주식회사 구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
CA2873949A1 (en) * 2012-05-24 2013-11-28 Ratiopharm Gmbh Dosage forms comprising apixaban and matrix former
US20150238425A1 (en) 2012-08-28 2015-08-27 Dsm Sinochem Pharmaceuticals Netherlands B.V. Mini-tablets
KR20170063954A (ko) 2014-10-07 2017-06-08 버텍스 파마슈티칼스 인코포레이티드 낭성 섬유증 막횡단 전도도 조절자의 조정제의 공-결정
WO2017146709A1 (en) * 2016-02-25 2017-08-31 Mylan Inc. A unique high-shear granulation process for improved bioavailability of rivaroxaban
GB201721065D0 (en) * 2017-12-15 2018-01-31 Ondosis Ab Delivery device for drug pellets
KR20190130411A (ko) 2018-05-14 2019-11-22 신일제약주식회사 아픽사반 약제학적 제제 및 그의 제조방법
WO2025150072A1 (en) * 2024-01-13 2025-07-17 Pulse Pharmaceuticals Pvt Ltd A stable oral pro-dispersion formulation and implementations thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60038097T2 (de) * 1999-02-22 2009-02-12 Merrion Research I Ltd. Feste orale dosierungsform enthaltend einen resorptionsverstärker
WO2000048589A1 (en) * 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
US6794412B1 (en) * 1999-03-11 2004-09-21 Bristol-Myers Squibb Pharma Company Treatment of thrombosis by combined use of a factor Xa inhibitor and aspirin
GB0114004D0 (en) * 2001-06-08 2001-08-01 Glaxo Group Ltd Chemical compounds
US20070196481A1 (en) * 2002-07-25 2007-08-23 Amidon Gregory E Sustained-release tablet composition
KR20040076203A (ko) * 2003-02-24 2004-08-31 주식회사 엘지생명과학 음식물-약물 상호작용을 방지하기 위한 경구 투여용약제학적 조성물 및 방법
DE102004062475A1 (de) * 2004-12-24 2006-07-06 Bayer Healthcare Ag Feste, oral applizierbare pharmazeutische Darreichungsformen mit modifizierter Freisetzung

Also Published As

Publication number Publication date
BRPI0716234A2 (pt) 2013-10-15
TW200824723A (en) 2008-06-16
CA2662542A1 (en) 2008-03-20
CN101516355A (zh) 2009-08-26
MX2009002669A (es) 2009-03-24
EP2061439A1 (en) 2009-05-27
IL197295A0 (en) 2009-12-24
KR20090052346A (ko) 2009-05-25
CL2007002618A1 (es) 2008-03-14
US20090285887A1 (en) 2009-11-19
WO2008031782A1 (en) 2008-03-20
AR062721A1 (es) 2008-11-26
EA200970267A1 (ru) 2009-08-28
JP2010502762A (ja) 2010-01-28
AU2007296311A1 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
PE20080661A1 (es) COMPOSICION FARMACEUTICA QUE COMPRENDE UN INHIBIDOR DEL FACTOR Xa
ES2529681T3 (es) Polímeros de colorante
PE20130574A1 (es) Nuevas formas de dosificacion de liberacion modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
CL2008000219A1 (es) Composicion farmaceutica de liberacion modificada que comprende a uno o mas ingredientes farmaceuticamente activos, con solubilidad dependiente del ph, un polimero controlador de la liberacion, agentes facilitadores de la gelificacion; procedimiento
BR112013025519A2 (pt) composição farmacêutica
CL2008002999A1 (es) Uso de una composicion farmeceutica que comprende trns-clominefo para preparar un medicamenteo util en el ratamiento de recuccion de los niveles de glucosa en ayunas en un varon.
AR075028A1 (es) Composicion farmaceutica solida que comprende amlodipina y losartan
UA103844C2 (ru) Фармацевтический состав, который содержит в матрице, которая подвергается эрозии, один или более эфиров фумаровой кислоты
CY1117143T1 (el) Νεα καρβονυλιωμενα (αζα)κυκλοεξανια ως προσδετες του d3 υποδοχεα ντοπαμινης
BRPI0716069A2 (pt) composto, composiÇço farmacÊutica, e, mÉtodo para tratar um distérbio
PE20141115A1 (es) Comprimido de desintegracion oral
CL2007000345A1 (es) Composicion farmaceutica que comprende una cantidad terapeuticamente efectiva de uno o mas agentes terapeuticos y una cantidad mejoradora de la absorcion intestinal de uno o mas agonistas de receptores de zonulina/zot; y uso de la composicion para tratar la diabetes.
SV2011003855A (es) Heteroarilos sustituidos
JO3044B1 (ar) نظام تناول جرعة لمنبه مستقبل s1p
PE20110943A1 (es) Formulacion oral solida de alisquireno
CR20120296A (es) Nuevos compuestos de espiropiperidina
CL2009000598A1 (es) Composicion farmaceutica oral que comprende particulas de liberacion pulsatil controlada en el tiempo (tpr), que contienen un farmaco poco soluble debilmente basico y un acido organico separados por una capa de liberacion sostenida, y particulas de liberacion rapida (rr); capsula que la comprende; y su uso para tratar emesis.
EA200802324A1 (ru) Новая форма введения рацекадотрила
CR20110209A (es) Composición farmacéutica sólida
CL2008003201A1 (es) Composicion farmaceutica que comprende 0,5 a 50 mg de gaboxadol o una sal farmaceuticamente aceptable de este, y uno o mas inhibidores de pat1 y/o uno o mas inhibidores de oat, en donde dicha composicion brinda un perfil plasmatico in vivo con un tmax superior a 20 minutos, util en tratamientos de trastornos del sueno.
PE20241347A1 (es) MODULAR LA EXPRESION DE APOLIPOPROTEINA (a)
CL2009000031A1 (es) Composicion de revestimiento que comprende; un poliol de poliester funcional de fosfato, insaturado en fibra del polister, sin inter-enlace en composicion de revestimiento, a traves de enlaces dobles en fibra del poliester; y un agente de curado.
MX2007008141A (es) Composicion farmaceutica de sustancias labiles en medio acido.
CL2007003251A1 (es) Compuestos derivados de 1h-pirazoles sustituidos, inhibidores de reacciones catalizadas por una quinasa; su procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; uso de los compuestos principales, utiles en el tratamiento del cancer.
PE20100471A1 (es) Composicion de liberacion pulsatil de sildenafil y proceso para prepararla

Legal Events

Date Code Title Description
FD Application declared void or lapsed